The Atlas Arteria Group (ASX: ALX) share price is in focus today after the company's independent directors recommended investors reject IFM's hostile takeover offer, stating the bid is too low and highly conditional.
Image source: Getty Images
What did Atlas Arteria report?
- IFM's hostile takeover offer is set at A$4.75 per stapled security (potentially A$5.10 if IFM's interest exceeds 45% before close).
- Offer price is below Atlas Arteria's previous closing price of A$4.79 (5 May 2026).
- The offer premium is less than 10% compared to the pre-offer closing price and around 3% above the 12-month average price.
- Atlas Arteria reaffirms distribution guidance of 40.0 cents per security for 2026.
- Each independent director intends to reject IFM's offer for their own ALX securities.
What else do investors need to know?
The board considers IFM's offer opportunistic, given recent market volatility and the share price trading well above the offer in the past year. Independent directors say the offer undervalues the company's global toll road portfolio and future growth opportunities. The company also notes IFM's current offer comes with over 50 separate sub-conditions, some of which are already incapable of being satisfied.
Atlas Arteria has issued a Right of First Offer in relation to its Chicago Skyway interest, a move unrelated to IFM's bid but relevant to the bid's conditions. The company continues to explore value-enhancing initiatives for securityholders, including asset recycling and potential strategic alternatives for its US assets.
What did Atlas Arteria management say?
Chair Debbie Goodin said:
This hostile, highly conditional takeover offer from IFM is opportunistic and materially undervalues Atlas Arteria. The Offer is designed to accelerate IFM's creep to effective control of Atlas Arteria without paying a fair premium to securityholders. The Independent Directors of Atlas Arteria recommend that securityholders reject the Offer. The Boards and management remain focused on continuing to deliver on the strategy to optimise company value and create value for all securityholders.
What's next for Atlas Arteria?
Atlas Arteria is preparing a detailed Target's Statement for securityholders, which will include an independent expert's report and set out the board's formal recommendation to reject IFM's offer. The statement will be provided at least 14 days before the offer closes.
The company says it will continue to update investors on material developments and remains focused on its strategy to optimise its asset portfolio and deliver distribution guidance.
Atlas Arteria share price snapshot
Over the past 12 months, Atlas Arteria's shares have declined 7%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.
